Your browser doesn't support javascript.
loading
Human ultrarare genetic disorders of sulfur metabolism demonstrate redundancies in H2S homeostasis.
Kozich, Viktor; Schwahn, Bernd C; Sokolová, Jitka; Krízková, Michaela; Ditroi, Tamas; Krijt, Jakub; Khalil, Youssef; Krízek, Tomás; Vaculíková-Fantlová, Tereza; Stiburková, Blanka; Mills, Philippa; Clayton, Peter; Barvíková, Kristýna; Blessing, Holger; Sykut-Cegielska, Jolanta; Dionisi-Vici, Carlo; Gasperini, Serena; García-Cazorla, Ángeles; Haack, Tobias B; Honzík, Tomás; Jesina, Pavel; Kuster, Alice; Laugwitz, Lucia; Martinelli, Diego; Porta, Francesco; Santer, René; Schwarz, Guenter; Nagy, Peter.
Affiliation
  • Kozich V; Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic. Electronic address: viktor.kozich@vfn.cz.
  • Schwahn BC; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester, United Kingdom.
  • Sokolová J; Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.
  • Krízková M; Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.
  • Ditroi T; Department of Molecular Immunology and Toxicology and the National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary.
  • Krijt J; Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.
  • Khalil Y; Genetics & Genomic Medicine Department, UCL GOS Institute of Child Health, London, UK.
  • Krízek T; Department of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czech Republic.
  • Vaculíková-Fantlová T; Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.
  • Stiburková B; Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic; Institute of Rheumatology, Prague, Czech Republic.
  • Mills P; Genetics & Genomic Medicine Department, UCL GOS Institute of Child Health, London, UK.
  • Clayton P; Genetics & Genomic Medicine Department, UCL GOS Institute of Child Health, London, UK.
  • Barvíková K; Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.
  • Blessing H; Kinder- und Jugendklinik, Universitätsklinikum Erlangen, Erlangen, Germany.
  • Sykut-Cegielska J; Department of Inborn Errors of Metabolism and Pediatrics, The Institute of Mother and Child, Warsaw, Poland.
  • Dionisi-Vici C; Division of Metabolism, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
  • Gasperini S; Metabolic Rare Diseases Unit, Department of Pediatrics, Fondazione MBBM, San Gerardo Hospital, Monza, Italy.
  • García-Cazorla Á; Inborn Errors of Metabolism Unit, Institut de Recerca Sant Joan de Déu and CIBERER-ISCIII, Barcelona, Spain.
  • Haack TB; Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
  • Honzík T; Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.
  • Jesina P; Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.
  • Kuster A; Center for Inborn Errors of Metabolism, Pediatric Intensive Care Unit, University Hospital of Nantes, Nantes, France.
  • Laugwitz L; Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany; Department of Neuropediatrics, Developmental Neurology and Social Pediatrics, University of Tübingen, Tübingen, Germany.
  • Martinelli D; Division of Metabolism, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
  • Porta F; Department of Pediatrics, Metabolic diseases, AOU Città della Salute e della Scienza, University of Torino, Torino, Italy.
  • Santer R; Department of Pediatrics, University Medical Centre Eppendorf, Hamburg, Germany.
  • Schwarz G; Institute of Biochemistry, Department of Chemistry, University of Cologne, Cologne, Germany. Electronic address: gschwarz@uni-koeln.de.
  • Nagy P; Department of Molecular Immunology and Toxicology and the National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary; Department of Anatomy and Histology, ELKH-ÁTE Laboratory of Redox Biology, University of Veterinary Medicine, Budapest, Hungary; Chemistry Institute, Univer
Redox Biol ; 58: 102517, 2022 12.
Article de En | MEDLINE | ID: mdl-36306676
ABSTRACT
Regulation of H2S homeostasis in humans is poorly understood. Therefore, we assessed the importance of individual enzymes in synthesis and catabolism of H2S by studying patients with respective genetic defects. We analyzed sulfur compounds (including bioavailable sulfide) in 37 untreated or insufficiently treated patients with seven ultrarare enzyme deficiencies and compared them to 63 controls. Surprisingly, we observed that patients with severe deficiency in cystathionine ß-synthase (CBS) or cystathionine γ-lyase (CSE) - the enzymes primarily responsible for H2S synthesis - exhibited increased and normal levels of bioavailable sulfide, respectively. However, an approximately 21-fold increase of urinary homolanthionine in CBS deficiency strongly suggests that lacking CBS activity is compensated for by an increase in CSE-dependent H2S synthesis from accumulating homocysteine, which suggests a control of H2S homeostasis in vivo. In deficiency of sulfidequinone oxidoreductase - the first enzyme in mitochondrial H2S oxidation - we found normal H2S concentrations in a symptomatic patient and his asymptomatic sibling, and elevated levels in an asymptomatic sibling, challenging the requirement for this enzyme in catabolizing H2S under physiological conditions. Patients with ethylmalonic encephalopathy and sulfite oxidase/molybdenum cofactor deficiencies exhibited massive accumulation of thiosulfate and sulfite with formation of large amounts of S-sulfocysteine and S-sulfohomocysteine, increased renal losses of sulfur compounds and concomitant strong reduction in plasma total cysteine. Our results demonstrate the value of a comprehensive assessment of sulfur compounds in severe disorders of homocysteine/cysteine metabolism and provide evidence for redundancy and compensatory mechanisms in the maintenance of H2S homeostasis.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Sulfure d'hydrogène Limites: Humans Langue: En Journal: Redox Biol Année: 2022 Type de document: Article

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Sulfure d'hydrogène Limites: Humans Langue: En Journal: Redox Biol Année: 2022 Type de document: Article
...